(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(0.12%) $82.73
(0.94%) $2.05
(-0.43%) $2 347.50
(-0.80%) $27.44
(-0.16%) $960.00
(-0.21%) $0.933
(-0.34%) $10.99
(-0.54%) $0.796
(1.55%) $93.30
0.35% $ 1.435
@ $1.954
Emitido: 14 feb 2024 @ 09:32
Retorno: -26.56%
Señal anterior: feb 7 - 16:00
Señal anterior:
Retorno: 1.24 %
Live Chart Being Loaded With Signals
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers...
Stats | |
---|---|
Volumen de hoy | 340 932 |
Volumen promedio | 430 161 |
Capitalización de mercado | 50.21M |
EPS | $0 ( 2024-04-04 ) |
Próxima fecha de ganancias | ( $-0.370 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.450 |
ATR14 | $0.00500 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Fortress Biotech, Inc. | Buy | 193 905 | COMMON STOCK, PAR VALUE $0.0001 |
2024-03-12 | Amit Sharma | Sell | 0 | Common Stock (Restricted) |
2024-02-28 | Oliviero James F Iii | Sell | 5 894 | COMMON STOCK |
2024-02-28 | Oliviero James F Iii | Sell | 9 056 | COMMON STOCK |
2024-02-28 | Gray William Garrett | Sell | 2 035 | Common Stock |
INSIDER POWER |
---|
82.65 |
Last 98 transactions |
Buy: 5 337 828 | Sell: 1 367 663 |
Volumen Correlación
Checkpoint Therapeutics Correlación
10 Correlaciones Más Positivas | |
---|---|
RMRM | 0.94 |
TLGT | 0.938 |
SVAC | 0.937 |
AGFY | 0.934 |
PAIC | 0.934 |
CCCC | 0.931 |
ALT | 0.931 |
JOAN | 0.93 |
VERU | 0.928 |
EYEG | 0.922 |
10 Correlaciones Más Negativas | |
---|---|
NETE | -0.95 |
MMAC | -0.934 |
STAY | -0.927 |
BNIXU | -0.92 |
CCRC | -0.92 |
NVCN | -0.912 |
DSPG | -0.911 |
XM | -0.909 |
FEXD | -0.901 |
AVEO | -0.896 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Checkpoint Therapeutics Correlación - Moneda/Commodity
Checkpoint Therapeutics Finanzas
Annual | 2023 |
Ingresos: | $103 000 |
Beneficio Bruto: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2023 |
Ingresos: | $103 000 |
Beneficio Bruto: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2022 |
Ingresos: | $192 000 |
Beneficio Bruto: | $-49.63M (-25 850.52 %) |
EPS: | $-7.57 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-10.15 |
Financial Reports:
No articles found.
Checkpoint Therapeutics
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico